<DOC>
	<DOCNO>NCT00824785</DOCNO>
	<brief_summary>To determine whether add panitumumab , antibody epidermal growth factor receptor ( EGFR ) , standard chemotherapy epirubicin , oxaliplatin capecitabine ( EOX ) , improve duration survival patient advance stomach oesophageal cancer .</brief_summary>
	<brief_title>REAL3 Trial Efficacy EOX With/Without Panitumumab Previously Untreated Adv OG Cancer</brief_title>
	<detailed_description>Multicentre phase III , open label , randomise control trial . Randomisation 1:1 Arm A EOX Arm B EOX + panitumumab . There pilot phase II study first 200 patient randomise primary endpoint interim analysis patient complete 6 month follow-up</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically verify inoperable locally advanced metastatic adenocarcinoma undifferentiated carcinoma oesophagus , oesophagogastric junction , stomach . Slides tumour tissue available centralise EGFR stain Unidimensionally measurable disease ( CT MRI per RECIST ) . No prior chemotherapy include previous adjuvant chemotherapy No prior radiotherapy include adjuvant radiotherapy . Patients receive palliative radiotherapy sit disease measurable may eligible discussed Chief Investigator . Male/female patient age ≥18 year . WHO Performance status 0 , 1 2 . Patients project life expectancy least 3 month . Completion baseline quality life questionnaire ( EORTC QLQ C30 ) . Adequate cardiac function ; formal measurement leave ventricular ejection fraction require clinically indicate . Adequate bone marrow function : absolute neutrophil count ( ANC ) ≥1.5x109/l ; white blood cell count ≥ 3x109/l ; platelet ≥ 100x109/l ; haemoglobin ( Hb ) ≥ 9g/dl ( posttransfusion ) . Adequate renal function : calculated creatinine clearance ≥50ml/minute . Adequate liver function : serum bilirubin ≤1.5x ULN ; ALT/AST ≤2.5x ULN ; ALP ≤3x ULN ( absence liver metastasis ) . If liver metastasis present , serum transaminase ≤5x ULN permit . Written informed consent must obtain patient studyspecific procedure perform ( see Section 12.0 ) . Note : Epidermal growth factor receptor ( EGFR ) positivity immunohistochemistry require study entry . Slides obtain previously collect paraffin embed archived specimen collect centrally EGFR stain . A multivariate analysis perform exclude effect EGFR status outcome measure Tumours squamous histology . Patients locally advanced oesophageal cancer suitable definitive chemoradiotherapy . Documented symptomatic brain metastasis and/or central nervous system metastases leptomeningeal disease . Previous chemotherapy radiotherapy . See Inclusion criterion note regard palliative radiotherapy . Any major surgery within 4 week prior start study treatment . Any prior treatment EGFR signal transduction direct therapy . Treatment nonpermitted medication . Clinically significant ( i.e . active ) cardiac disease e.g . symptomatic coronary artery disease , uncontrolled cardiac dysrhythmia , myocardial infarction within last 12 month . Patients history clinically significant cardiac failure exclude study entry . History interstitial lung disease ( e.g. , pneumonitis pulmonary fibrosis ) evidence interstitial lung disease baseline chest CT scan . Known peripheral neuropathy &gt; Grade 1 ( absence deep tendon reflexes sole neurological abnormality render patient ineligible ) . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication ( administration capecitabine nasogastric jejunostomy feed tube permit ) . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . Known hypersensitivity panitumumab , component EOX regimen , constituent agent . Known positive test human immunodeficiency virus ( HIV ) infection , hepatitis C virus , acute chronic active hepatitis B infection . Other clinically significant disease comorbidity may adversely affect safe delivery treatment within trial . Female patient may pregnant breastfeeding . Potential female patient childbearing potential must negative pregnancy test within 7 day prior randomisation , amenorrhea 2 year . Patients childbearing potential consenting use adequate contraceptive precaution abstinence course study 6 month last study drug administration female , 1 month male . Any malignancy within last 5 year ( curatively treat basal cell carcinoma skin and/or situ carcinoma cervix ) . Treatment another investigational agent within 30 day commence study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>epirubicin</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>capecitabine</keyword>
	<keyword>panitumumab</keyword>
</DOC>